Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease.

Respiratory Medicine（2019）

引用 25|浏览18

暂无评分

摘要

Treatment-emergent adverse effects reported for >5% of patients that received revefenacin 175 μg and tiotropium 18 μg.Image 1

查看译文

关键词

COPD,Long-acting muscarinic antagonist,Once daily,Nebulized therapy,Safety,Revefenacin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要